Lupin gains FDA nod for generic Neurontin tablets
Lupin has received final approval from the Food and Drug Administration for its generic Neurontin (gabapentin) tablets.
The tablets are a generic version of Pfizer’s Neurontin tablets indicated for the treatment of postherpetic neuralgia in adults and adjunctive therapy in the treatment of partial onset seizures with and without secondary generalization in those 3 years old and older with epilepsy.
Lupin’s generic will be available in 600- and 800-mg dosage strengths. According to IQVIA data, the products had annual sales of roughly $180 million.
The tablets are a generic version of Pfizer’s Neurontin tablets indicated for the treatment of postherpetic neuralgia in adults and adjunctive therapy in the treatment of partial onset seizures with and without secondary generalization in those 3 years old and older with epilepsy.
Lupin’s generic will be available in 600- and 800-mg dosage strengths. According to IQVIA data, the products had annual sales of roughly $180 million.